- Home
- FAX vs AKBA Comparison
FAX vs AKBA Comparison
Compare FAX & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FAX | AKBA |
|---|---|---|
| Founded | 1986 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 632.9M | 729.1M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | FAX | AKBA |
|---|---|---|
| Price | $15.22 | $1.63 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $6.25 |
| AVG Volume (30 Days) | 833.6K | ★ 3.3M |
| Earning Date | 01-01-0001 | 11-10-2025 |
| Dividend Yield | ★ 12.09% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $225,071,000.00 |
| Revenue This Year | N/A | $52.38 |
| Revenue Next Year | N/A | $22.45 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 32.49 |
| 52 Week Low | $2.33 | $1.45 |
| 52 Week High | $2.84 | $4.08 |
Technical Indicators
Market Signals| Indicator | FAX | AKBA |
|---|---|---|
| Relative Strength Index (RSI) | 44.90 | 41.85 |
| Support Level | $15.19 | $1.59 |
| Resistance Level | $15.38 | $1.61 |
| Average True Range (ATR) | 0.13 | 0.08 |
| MACD | 0.01 | 0.05 |
| Stochastic Oscillator | 26.11 | 70.59 |
Price Performance
Historical ComparisonAbout FAX abrdn Asia-Pacific Income Fund Inc.
Aberdeen Asia-pacific Income Fund Inc is a United States-based closed-end, non-diversified management investment company. Its principal investment objective is to seek current income along with capital appreciation. The fund invests in Asian debt securities, Australian debt securities, European debt securities and others.
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.